Background: Limited data exist on indicators of durable pulmonary vein isolation
recurrence, high success rates can be expected when touch-up ablation of EPVR sites is performed.
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| INTRODUCTION
Cryoballoon ablation (CBA) has emerged as an alternative to radiofrequency (RF) ablation of atrial fibrillation (AF). 1 Pulmonary vein isolation (PVI) performed with a second-generation cryoballoon has been highly successful in cases of paroxysmal AF and is comparable to PVI performed by point-by-point RF ablation [2] [3] [4] [5] [6] or even contact force (CF)-guided RF ablation. 7, 8 However, despite efforts to properly position the cryoballoon to establish good balloon surface-tissue contact, some patients experience early PV reconduction (EPVR) in the form of residual PV potentials, spontaneous PV-left atrium (LA) reconnection, or adenosine triphosphate (ATP)-provoked dormant PV conduction (DC). 9 Balloon temperature measured by the console at different time points, for example, at 30 and 60 seconds, and nadir point and the time to PVI during CBA have been shown to be useful in predicting successful PVI. 10 However, the best predictor of durable PVI has not been established. Further, even when good balloon surface-tissue contact is achieved, the balloon temperature and time to PVI differ between patients and between PVs because of the different thicknesses of the PV wall and histologic characteristics of the myocardial sleeves. 11, 12 Thus, in the retrospective study described herein, we first investigated relations between the occurrence of EPVR after CBA and the following four variables: balloon temperature at different time points, time from the initial delivery of cryoenergy to completion of PVI, balloon temperature for each of the 4 PVs at during the PVI, and time to PVI for each of the four PVs.
A recent randomized clinical trial showed improved clinical outcomes after elimination of dormant PV conduction by delivery of additional RF energy to ATP-provoked DC sites, 13 whereas other randomized trials showed no superiority of ATP-or adenosineguided PVI over conventional PVI. 14, 15 Because it remains unclear whether additional delivery of RF energy to EPVR sites affects clinical outcomes of CBA, we also investigated the relation between additional RF ablation of EPVR sites and recurrence of AF after CBA.
| ME TH ODS

| Study patients
Included in our study were 130 consecutive patients who had undergone cryoballoon-based PVI for drug-refractory AF (paroxysmal AF, n = 84; persistent AF, n = 46) at Nihon University Itabashi Hospital between September 2014 and June 2017. All patients had provided informed consent for use of their anonymized clinical data for research purposes, and our access to the patient information was approved by the hospital's institutional review board.
| Cryoballoon ablation
Cryoballoon ablation was performed with a 28-mm second-generation catheter (Achieve, Medtronic) was placed in the LA through the 15Fr deflectable sheath. The balloon was then inflated and advanced successively to each PV ostium to establish optimal PV occlusion, determined by the absence of contrast leakage. To avoid overwedging of the balloon inside the PVs, we used the "proximal-seal" technique for all RSPVs and LSPVs; that is, we withdrew the inflated balloon until a small leak was observed and then repositioned the balloon slightly. 9 Cryoenergy was delivered to each PV after occlusion was established.
The freeze time for ablation of each PV antrum was 180 seconds.
Whenever possible, the PV potentials were monitored by means of an inner lumen mapping catheter. To avoid phrenic nerve injury, the phrenic nerve was monitored continuously during ablation of the right superior and inferior PVs (RSPV and RIPV, respectively) by systematically pacing the right phrenic nerve from the superior vena cava. 16 
| PV diameter measurements
We measured the PV ostial diameters using 3D CT images. The maximum and minimum diameters were measured at the PV ostium, which was defined based on the geometry obtained from 3D CT images.
| Ablation-related variables
Balloon temperature, measured by the console during CBA targeting each of the four PVs, was determined at 30 seconds, at 60 seconds, and the nadir point, and the thaw times to 0°C were also determined. When PV potentials were recorded during CBA, the balloon temperature and time from the first cryoenergy application to achievement of PVI, that is, to occurrence of dissociated PV conduction or to disappearance of the PV potential, were determined.
| Postablation follow-up
All antiarrhythmic drugs were resumed after ablation but then typically stopped after a 3-month blanking period. In some patients, antiarrhythmic drugs were continued beyond this point on the basis of physician and/or patient preference even in the absence of AF recurrence. All patients underwent routine follow-up examination at our outpatient clinic 2 weeks and 1 month after ablation and at 1-to-3-month intervals thereafter for at least 6 months. Twenty-four-hour 
| Residual leak
Residual leaks were observed in 241 of the 518 PVs (46.5%). 
| PV diameter
The maximum LSPV and RIPV ostial diameters were significantly larger for the PVs with early reconnections than for those that without 
| Balloon temperatures
Balloon temperatures at each time point were significantly higher for the PVs that had early reconnection than those that did not: 30 seconds (−27 ± 5.7°C vs −31 ± 5.5°C, respectively; P < 0.0001), 60 seconds (−36 ± 5.6°C vs −41 ± 5.4°C, respectively; P < 0.0001), and the nadir point (−41 ± 7.4°C vs −49 ± 7.0°C, respectively; P < 0.0001). The interval thaw time to 0°C was significantly shorter in the PVs that showed early reconnection than in those that did not (5.8 ± 3.7 seconds vs 9.9 ± 4.9 seconds, respectively; P < 0.0001) ( Table 2 and (Table 3) . Freedom from AF was equivalent between T A B L E 2 Balloon temperature at each time point and balloon temperature/time to the PVI for PVs with and without early reconnection after cryoballoon ablation Figure 3 ). The AF recurrence rate was low among patients with persistent AF and equivalent to that among patients with paroxysmal AF (11% vs 14%, respectively; P = 0.58). However, the use of bepridil after ablation was significantly more prevalent among patients with persistent AF than among those with paroxysmal AF (57% vs 21%, respectively; P < 0.0001).
| DISCUSSION
Our main study findings were as follows: First, EPVR was related to male sex, younger age (age < 65 years), persistent AF, and a low CHA2DS2-VASC score. Second, residual leaks were more prevalent and the PV diameter longer for PVs with EPVR than for those with- 
| Balloon temperatures and EPVR
We found balloon temperature at 30 seconds, at 60 seconds, and at the nadir point to be significantly higher and the interval thaw time to 0°C to be significantly shorter in patients with EPVR than in those without EPVR. Touch-up ablation for residual PV potentials after CBA has been reported for 2%-17% of PVs. [17] [18] [19] The need for touch-up ablation to achieve PVI reached 17% of our targeted PVs and affected 47% of our patients. Patients in most of the recently reported studies had paroxysmal AF, whereas persistent AF was quite prevalent among our study patients (35%). It might be that a balloon of 28 mm in diameter is too small for good balloon-tissue surface contact when the PV antrum is large, as in cases of persistent AF. Our patients with EPVR were likely to have persistent AF, and the LA diameter and LA volume were greater in these patients than in the other patients. According to our multivariable analysis, age > 65 years was the strongest predictor of EPVR. We speculate 
F I G U R E 2 ROC curves for prediction of absence of EPVR according to cryoballoon temperature at 30 s (A), at 60 s (B), at the nadir point (C), interval thaw time to 0°C (D), and time to PVI (E). ROC, receiver operating characteristic; EPVR, early pulmonary vein reconduction; AUC, area under the curve; PVI, pulmonary vein isolation that the tissue in young patients is healthier than that in older patients, thus requiring greater cryothermal energy to isolate the PVs, and this issue might be compounded by inadequate balloon-tissue surface contact if a young patient is being treated for persistent AF. Indeed, a larger maximum PV ostial diameter potentially leading to an inadequate balloon-tissue surface contact in such patients as persistent AF was strongly associated with EPVR. The association was prominent especially with the LSPV and RIPV. In most recently reported studies, PVI was assessed with an Achieve circular mapping catheter, 18, 20 and thus, the PV potentials were underestimated especially in the antral region. 21 We searched meticulously for any residual PV potentials by means of 3D voltage remapping, and we looked for potentials not only inside the PVs but also in the antral region.
Thus, the characteristics of our patients and our procedure might account for the incidence of EPVR in our patient series.
Adequate balloon temperature following PV occlusion with good balloon-tissue surface contact is important for successful PVI. PV occlusion was generally established by contrast leakage. Our data showed the presence of a residual leak leads to the presence of EPVR, which is well in line with the other reports. [3] [4] [5] [6] [7] [8] [9] [10] [17] [18] [19] [20] We found that a balloon temperature less than −27°C at 30 seconds, less than −37°C at 60 seconds, and less than −44°C at the nadir point and that a >6-seconds interval thaw time to 0°C were all fairly accurate for predicting the absence of EPVR. Similarly, several reported studies of second-generation CBA have shown achievement of a balloon temperature of −40°C within the first 60 seconds of cryoenergy application to be an independent predictor of durable PVI. 22 In previously reported studies, a minimal temperature of less than −51°C
was shown to predict successful PVI without acute PV reconduction. 10, 18 In our study, the nadir balloon temperature also had the best prognostic performance for the absence of EPVR, but clinically, balloon temperature during the first 30 seconds or 60 seconds of CBA would be more important for early prediction of PV reconnections. For example, if the balloon temperature at 30 seconds is greater −27°C or at 60 seconds is greater than −37°C, it would be better to terminate the ablation and reposition the balloon so that a better temperature can be achieved. Further, in our study, < 65 seconds for the time to PVI was shown to be a good predictor for prevention of EPVR. A previous study showed 60 seconds to PVI to be predictive of sustained success (i.e, absence of reconduction). 22, 23 Our study showed that, in addition to there being an optimum temperature to be reached at each of various time points, the optimum time to isolation varies between PVs. The optimum time to PVI appears to be significantly longer, and balloon temperature appears to be lower for the LSPV and RIPV than for the LIPV and RSPV. We to PVI might also be explained in part by a thick LSPV or RIPV sleeve. 12 Therefore, the CBA time can be shortened if there is a potential risk of phrenic verve injury or esophageal injury during ablation of the RSPV or LIPV located close to these collateral tissues.
We also found an interesting finding that the maximum RSPV ostial diameter correlated negatively with balloon temperatures, but not for the other PVs. This suggests that the balloon is easily moved to the distal PV when the operators place the balloon in an enlarged RSPV ostium to establish appropriate balloon-tissue surface contact.
Thus, careful balloon manipulation to prevent phrenic nerve injury or PV stenosis will be needed especially for cases in whom the PV ostium in the RSPV is large.
| Clinical outcomes after CBA
Clinical AF recurrence at a median follow-up of 13.4 months was detected in only 17 (13%) of 130 study patients. Recent studies comparing CF-guided RF ablation with CBA have shown statistical equivalence between the two technologies. 7, 8 In our study, the use of class I antiarrhythmic drugs was associated with AF recurrence, because those were often administered due to AF recurrence. Other than that, we did not find any predictors of AF recurrence, including the presence of EPVR or the nadir balloon temperature. In standard RF-based PVI, spontaneous PV reconduction and DC have been reported to predict PV reconduction or AF recurrence despite additional touch-up RF application to the involved sites. [24] [25] [26] We observed spontaneous early PV-LA reconnection and DC in 3% and 5% of PVs in 1% and 16% of patients, respectively, rates lower than those reported for spontaneous PV reconduction or DC when RFbased PVI is performed. 27, 28 This was possibly because CBA, in comparison with RF-based ablation, produces wider and thus more durable lesions around the PV ostium. 9 The durability of CBA-based PV lesions may have lessened the possibility of AF recurrence that would have arisen from PV reconnections. PVI is the only established strategy for both persistent AF and paroxysmal AF. 29, 30 Interestingly, in our patient series, the AF recurrence rate among patients with persistent AF was very low (only 10.9%) and equivalent to that among the patients with paroxysmal AF. Although the use of bepridil was more prevalent among our patients with persistent AF than among those with paroxysmal AF, the wide, durable PV lesions created by CBA and the touch-up RF ablation to EPVR sites identified by 3D remapping may, in part, confer favorable outcomes even in patients with persistent AF.
| Study limitations
Our study was limited by the size of the patient groups. Nonetheless, the acute and chronic post-CBA outcomes, including AF recurrence, were similar to those reported by other investigators.
We did not analyze the CBA lesions and PV reconnection sites in the chronic phase in patients in whom AF recurred, and therefore, it remains unclear whether the recurrence was due to PV reconnections, non-PV triggers, or a remodeled LA substrate. Finally, time to PVI can be used only when PV potentials are recorded by the circular mapping catheter during the CBA, but unfortunately, PV potentials were not always recorded in the inferior PVs that frequently had an EPVR. Nonetheless, time to PVI will be useful in cases in whom PV potentials can be recorded in the inferior PVs. Even in cases in whom PV potentials are not recorded, we can use alternative indicators of balloon temperatures for predicting an absence of EPVR.
| CONCLUSION S
We found the nadir cryoballoon temperature to have the best predictive performance for absence of EPVR after ablation for AF. Time to PVI < 65 seconds may be a useful variable predictive of durable PVI when a real-time recording of PV potentials is obtained, but both the balloon temperature and time to PVI differ between the 4
PVs. Procedural data can be used to determine whether CBA is performed safely and effectively. Even though inappropriate nadir balloon temperatures leading to the EPVR are observed, high and equivalent success rates can be expected for patients with paroxysmal and those with persistent AF if touch-up RF ablation of EPVR sites identified by 3D voltage mapping is performed.
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